Dr. David Sinclair of Harvard has made a statement that has shaken the scientific community: "The first human being who will live to be 150 years old has probably already been born. And they won't look like a centenarian - they'll look 60." This claim, once confined to science fiction, is now supported by solid scientific data.
Cellular reprogramming therapies, inspired by the work of Nobel laureate Shinya Yamanaka, now allow human cells to be rejuvenated by 20 to 30 years in the laboratory. The first clinical trials on humans, launched in 2025, show promising results in the regeneration of cardiac and brain tissue.
Artificial intelligence is accelerating these discoveries exponentially. DeepMind's AlphaFold has identified 200 new therapeutic targets against aging by analyzing the protein structures of 200 million molecules. Senolytic drugs – which eliminate failing old cells – are entering advanced clinical phases.
The social implications are dizzying: retirement, healthcare systems, family structures, labor markets – everything will need to be rethought for a society where active lifespan could exceed 100 years. Economists are talking about a "longevity revolution" as profound as the industrial revolution.
The ethical questions are immense. If these treatments initially cost hundreds of thousands of euros, the risk of a "two-tiered immortality" worries philosophers and policymakers. The WHO calls for universal access to longevity technologies.
